Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Late cornified envelope protein 3C (LCE3C) is a structural component of the cornified envelope in the stratum corneum, encoded within the epidermal differentiation complex on chromosome 1q21[4][5][6]. It participates in skin barrier formation and repair, keratinocyte differentiation, and exhibits innate antimicrobial activity against a range of Gram-positive and Gram-negative bacteria[4][5][6]. LCE3C is implicated in host defense mechanisms and maintaining cutaneous integrity. Genetic deletion (LCE3C_LCE3B-del) is associated with increased risk for psoriasis and allergic contact dermatitis, likely by compromising the physical skin barrier and facilitating environmental allergen and pathogen penetration[1][3][4]. Its physiological role centers on skin structure and immunity rather than signaling or cell regulation, and it is not considered a conventional therapeutic drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Late cornified envelope protein 3C (LCE3C).